Merkulov Yu A, Magomedova A M, Biglova A N, Gamburg A M, Tashanova B A, Merkulova D M
Moscow Centre for Research and Practice in Medical Rehabilitation, Restorative and Sports Medicine, Moscow, Russia.
Scientific Research Institute of General Pathology and Pathophysiology, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(2):31-37. doi: 10.17116/jnevro202112102131.
To evaluate the efficacy of the AChE inhibitor ipidacrine when added to traditional therapy in outpatients with tunnel syndromes (TS) based on clinical, neurophysiological and psycho-emotional indicators.
Ninety-two patients with a verified diagnosis of TS were randomized into a main group (MG), in which ipidacrine was added to the therapy (=50), and a control group (CG), which received conventional therapy (=42). Clinical neurological examination, provocative (Tinel, Falen, Goldberg finger compression, elevator and tourniquet) tests, pain questionnaires (VAS, DN4, PainDetect, Pain Disability Index), Beck's depression scale, the Spielberger Trait and State Anxiety Inventory, electroneuromyography (ENMG) were used.
Most of the examined subjects were patients with mild TS without muscle weakness or amyotrophy (80%). In the main group, there was a significant decrease in hypoesthesia, normalization of provocative tests, the increase of SNAP amplitudes, as well as nerve conduction velocities over motor and sensory fibers of the studied nerves (<0.05). Besides, the regression of neuropathic pain syndrome was objectified according to VAS, DN4 and PainDetect scales, which indexes decreased significantly (<0.01) in the course of therapy combined with ipidacrine. The positive dynamics, in its turn, contributed to the reduction of depression according to Beck's depression scale, comorbid chronic pain syndrome and improvement of patients' quality of life according to Pain Disability Index (<0.05). There was no significant improvement of clinical and neurophysiological parameters in the CG (>0.05). There were no significant differences in the assessment of pain, depression and quality of life (>0.05), except for a decrease in VAS scores (=0.03).
In patients treated with traditional therapy in combination with ipidacrine, the follow-up study after 4 weeks showed the reliable positive dynamics of clinical, neurophysiological and psycho-emotional indicators without application of psychoactive drugs.
基于临床、神经生理学和心理情绪指标,评估在传统治疗基础上加用乙酰胆碱酯酶抑制剂阿地溴铵对患有腕管综合征(TS)的门诊患者的疗效。
92例确诊为TS的患者被随机分为主要治疗组(MG,n = 50),该组在治疗中加用阿地溴铵,以及对照组(CG,n = 42),该组接受传统治疗。采用临床神经学检查、激发试验(Tinel试验、Falen试验、Goldberg手指压迫试验、抬举试验和止血带试验)、疼痛问卷(视觉模拟评分法、DN4问卷、疼痛检测量表、疼痛残疾指数)、贝克抑郁量表、斯皮尔伯格特质和状态焦虑量表、神经肌电图(ENMG)。
大多数受检者为轻度TS患者,无肌肉无力或肌萎缩(80%)。在主要治疗组中,感觉减退显著减轻,激发试验结果正常化,感觉神经动作电位(SNAP)波幅增加,以及所研究神经的运动和感觉纤维的神经传导速度加快(P < 0.05)。此外,根据视觉模拟评分法、DN4问卷和疼痛检测量表,神经性疼痛综合征得到缓解,在联合阿地溴铵治疗过程中,这些指标显著下降(P < 0.01)。这种积极的变化反过来又有助于根据贝克抑郁量表减轻抑郁,缓解合并的慢性疼痛综合征,并根据疼痛残疾指数改善患者的生活质量(P < 0.05)。对照组的临床和神经生理学参数无显著改善(P > 0.05)。除视觉模拟评分法得分下降外(P = 0.03),在疼痛、抑郁和生活质量评估方面无显著差异(P > 0.05)。
在接受传统治疗联合阿地溴铵治疗的患者中,4周后的随访研究显示,在未使用精神活性药物的情况下,临床、神经生理学和心理情绪指标呈现出可靠的积极变化。